SITE MAP | SEARCH | ENGLISH Last paid: 98.50 Lowest today: 97.25 Highest today: 99.50 HOME THE MEDIVIR GROUP RESEARCH AND DEVELOPMENT DRUG INVESTOR PRESS ROOM AVAILABLE POSITIONS PLUG Visit our Press Room if you want to read the press releases we send out or see what the media writes about Medivir. Press room Research and Development At Medivir, we work in all phases of pharmaceutical research, partly with projects that we run under our own auspices and partly in projects together with various partners. Read more about our research and development Read more about our project portfolio Drug Within the Medivir Group, we have several prescription drugs for the treatment of diseases in a number of different therapy areas. Read more about our medicines MIV-802 has been selected as the drug candidate “We are very pleased with the preclinical profile of MIV-802 with high antiviral activity in HCV replication models, attractive pharmacokinetic properties, and an excellent profile in a broad range of both mechanism-based and general safety studies. We believe that MIV-802 is well placed to be a very valuable supplement to the drugs available today to treat and cure hepatitis C-infected patients. ” RICHARD BETHELL EVP DISCOVERY RESEARCH To the press release Upcoming activities Jan 8 Medivir presents at SEB Nordic Seminar in Copenhagen Jan 11 Medivir will attend the JP Morgan Healthcare Conference in San Francisco on January 11-14 Feb 27 Year-end report, 1 January - 31 December 2014 All upcoming activities PAGE UPDATED NO LATER THAN DECEMBER 22, 2014